Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery

Launched by INSTITUTO NACIONAL DE CARDIOLOGIA IGNACIO CHAVEZ · Jul 24, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effect of a supplement called nicotinamide riboside (NR) on kidney function in patients who are undergoing heart valve replacement surgery. Acute kidney injury (AKI) can be a serious complication after heart surgery, and there are currently no specific treatments for it. The researchers want to see if NR can help improve kidney function and reduce the risk of AKI in these patients.

To participate in the trial, patients should be scheduled for heart valve replacement surgery and be able to give informed consent. However, individuals who have certain conditions, such as specific allergies, low platelet counts, or severe kidney issues, are not eligible. The study is not yet recruiting participants, but those who join can expect to take the supplement during their surgery and will be monitored for its effects on their kidney health. This trial is important because finding effective treatments for AKI could significantly improve recovery outcomes for patients undergoing cardiac surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Heart valve replacement surgery
• • Sign of informed consent
• Exclusion Criteria:
• • Allergy to any of the components
• • Platelet count less than 100,000
• • Weight less than 50Kg or over 100Kg
• • Any type of infectious disease (e. g, Endocarditis)
• • GFR less or equal to 15ml/min/m2 or with renal replacement therapy
• • IV or oral contrast medium 72 hrs prior recruitment
• • LRA 7 days prior to surgery